Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II fulvestrant study in ER-positive recurrent or metastatic low-grade gynecologic cancers
NL-OMON50189Phase 2Recruiting
- Sponsor
- UZ Leuven
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in uterine sarcoma, endometrial cancer (EC), Sex cord-stromal tumors (SCST) and 1 more, sponsored by UZ Leuven. Primary endpoint: Objective response rate. Started Jun 2019; status: recruiting.
02
Drugs
fulvestrant
03
Conditions
uterine sarcomaendometrial cancer (EC)Sex cord-stromal tumors (SCST)low-grade serous ovarian carcinoma (LGSOC)
Beyond the preview
Go deeper on NL-OMON50189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50189.